Details for New Drug Application (NDA): 018749
✉ Email this page to a colleague
NDA 018749 describes LITHOSTAT, which is a drug marketed by Mission Pharma and is included in one NDA. It is available from one supplier. Additional details are available on the LITHOSTAT profile page.
The generic ingredient in LITHOSTAT is acetohydroxamic acid. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the acetohydroxamic acid profile page.
The generic ingredient in LITHOSTAT is acetohydroxamic acid. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the acetohydroxamic acid profile page.
Summary for 018749
| Tradename: | LITHOSTAT |
| Applicant: | Mission Pharma |
| Ingredient: | acetohydroxamic acid |
| Patents: | 0 |
Pharmacology for NDA: 018749
| Mechanism of Action | Urease Inhibitors |
Suppliers and Packaging for NDA: 018749
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| LITHOSTAT | acetohydroxamic acid | TABLET;ORAL | 018749 | NDA | Mission Pharmacal Company | 0178-0500 | 0178-0500-01 | 100 TABLET in 1 BOTTLE (0178-0500-01) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 250MG | ||||
| Approval Date: | May 31, 1983 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
